METHODS	After an initial subcutaneous ( s.c. ) loading phase in each treatment arm , patients received s.c. maintenance therapy with secukinumab 300 mg every 2 weeks ( q2w ) , secukinumab 300 mg monthly ( q4w ) , or placebo in the SHIELD study ; secukinumab 300 mg q2w , secukinumab 300 mg q4w , secukinumab 150 mg q4w , or placebo in the INSURE study ; or secukinumab 300 mg q2w , secukinumab 300 mg q4w , secukinumab 150 mg q4w , or placebo in the ENDURE study .\